Lucy Scientific's Fiscal Year: Operating Expenses Rise As Accumulated Deficit Hits Over $44M
Lucy Scientific's Fiscal Year: Operating Expenses Rise As Accumulated Deficit Hits Over $44M
Psychedelics company Lucy Scientific Discovery Inc. (NASDAQ:LSDI) reported its full-year results for the period ended June 30, 2023. Numbers show:
Psychedelics 公司 露西科學發現 Inc.（納斯達克股票代碼：LSDI）公佈了截至2023年6月30日的全年業績。數字顯示：
-
Total cash held of $1.67 million, vs. $53,379 held in June 30, 2022.
-
Net product sales of $7,048 vs. zero in the prior fiscal year, reportedly owing to sales of Lucy's new microdose mushroom capsules.
-
Working capital expenses of $2.71 million, vs. $5.81 million by June 30, 2022.
-
Operating expenses totaled $5.85 million, a 68.5% YoY increase as compared to $3.47 million in the prior FY.
-
Net cash flows used in operating activities totaled $4.27 million, a 76.4% YoY increase compared to prior FY's $2.42 million.
-
Total net loss of $8.99 million (or $0.71 per share, basic and diluted) vs. the prior year's $5.86 million (or $0.68 per share, basic and diluted.)
-
Accumulated deficit of $44.4 million, around a 25% YoY increase compared to the $35.4 million in 2022's third quarter close.
-
持有的現金總額爲167萬美元，而2022年6月30日持有的現金爲53,379美元。
-
據報道，由於露西的新型微劑量蘑菇膠囊的銷售，產品淨銷售額爲7,048美元，而上一財年的銷售額爲零。
-
營運資金支出爲271萬美元，而截至2022年6月30日爲581萬美元。
-
運營支出總額爲585萬美元，同比增長68.5％，而上一財年的347萬美元爲347萬美元。
-
用於經營活動的淨現金流總額爲427萬美元，與上一財年的242萬美元相比，同比增長76.4％。
-
淨虧損總額爲899萬美元（合每股虧損0.71美元，基本虧損和攤薄後每股虧損0.71美元），去年同期爲586萬美元（合每股虧損0.68美元，基本和攤薄後每股虧損0.68美元）。
-
累計赤字爲4,440萬美元，與2022年第三季度收盤時的3540萬美元相比，同比增長約25％。
The company acutely increased its accumulated deficit during the yearly period, despite new M&As closed during the period, as first reported
正如首次報告的那樣，儘管在此期間完成了新的併購，但該公司在本年度的累計赤字急劇增加
Green Market Report's Adam Jackson.
《綠色市場報告》的亞當·傑克遜。
Partnerships, Acquisitions & Product Offerings
合作伙伴關係、收購和產品供應
During the closing fiscal year, Lucy closed numerous deals with different businesses and partners, including:
在最後一個財年，露西與不同的企業和合作夥伴達成了多筆交易，包括：
-
An all-stock acquisition of long-standing cannabis media outlet High Times Holding's IP, brand and licensing business.
-
The acquisition of e-commerce platform and plant-based wellness brand company Blue Sky Wellness.
-
Partnership with specialized firm Pramantha Group toward attaining key government contracts and grants.
-
Development and offer of new Amanita Muscaria mushroom products through online stores and retail channels.
-
Amendment to Canadian Dealer's License enabling the production of cocaine and heroin toward safe supply offering for governments' public health responses to the drug crisis.
-
對歷史悠久的大麻媒體High Times Holding的知識產權、品牌和許可業務進行全股收購。
-
收購電子商務平台和植物性健康品牌公司Blue Sky Wellness。
-
與專業公司Pramantha Group合作，以獲得重要的政府合同和補助金。
-
通過在線商店和零售渠道開發和提供新的Amanita Muscaria蘑菇產品。
-
加拿大經銷商許可證修正案允許生產可卡因和****用於安全供應，爲政府應對毒品危機的公共衛生措施提供安全供應。
See Also: Another Company Approved To Begin Production Of Psychedelics Under Canadian Dealers License
另見：另一家公司獲准在加拿大經銷商許可下開始生產迷幻藥
-
Team up with Canadian advocacy organization TheraPsil for the
-
advancement of legal medical psilocybin access and research.
-
Commercial sale of psilocybin to Hadassah BrainLabs, the center for psychedelics research at the Hebrew University in Jerusalem.
-
與加拿大倡導組織 TherapSil 合作
-
推進合法醫療迷幻藥的獲取和研究。
-
將迷幻藥商業化出售給耶路撒冷希伯來大學迷幻藥研究中心Hadassah BrainLabs。
See the company's full financial results and discussion breakdown here.
在此處查看該公司的完整財務業績和討論細目。
Photo: Benzinga edit with photo by Pexels and Shutterstock.
照片：Benzinga 編輯，照片由 Pexels 和 Shutterstock 拍攝。
譯文內容由第三人軟體翻譯。